.jpg)
2 hours ago
3
Article content
- Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow’s feet (lateral canthal lines)1-3
- Dysport® (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction after treatment of frown lines will also be presented4,5
- Galderma will also present a Masterclass on the science behind Relfydess, demonstrating how the company is shaping the future of neuromodulation
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
ZUG, Switzerland — Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which expert speakers will delve into the science and clinical data behind Relfydess.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed neuromodulator that delivers advanced performance. As the only company with a portfolio of neuromodulators, we’re building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitioners.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA |
Article content
Relfydess presentations include two encore post-hoc subgroup analyses of pooled phase III READY program data in moderate-to-severe frown lines and crow’s feet. These data showed:
Article content
- >98% and >88% investigator-assessed responder rates after one month of treatment in patients with frown lines and crow’s feet, respectively3
- >24 weeks median time to return to baseline severity for both frown lines and crow’s feet, as assessed by both patients and investigators2
Article content
Additionally, new Relfydess data includes results from an in vivo head-to-head study of Relfydess and OnabotulinumtoxinA showing similar and limited levels of diffusion in a rat model.6 Together, these analyses provided further evidence to support Relfydess’ rapid onset and efficacy through six months regardless of previous neuromodulator treatment, robust safety profile, high patient satisfaction, and improved well-being.2,3,6 Galderma will also be hosting a Relfydess Masterclass at TOXINS 2026 in which expert speakers, Dr. Joanna Czuwara and Dr. Birgit Blessman-Gurk, will discuss clinical data, real-world treatment experience, and the science behind Relfydess’ PEARL Technology. The session will feature insights into its rapid onset, long duration, and scientific differentiation principles and will take place from 15:50 – 16:20 CET on Thursday, January 15 in the Educational Theatre.
Article content
Article content
Furthermore, abstracts investigating patient and practitioner satisfaction when using Dysport to treat frown lines will also be presented at the conference, including results from a real-world study of repeated Dysport treatment in China showing up to 100% patient satisfaction three weeks after three treatment cycles.4,5Establishing clear leadership in neuromodulation Galderma’s data and activities at TOXINS 2026 demonstrate how its innovative and unique neuromodulator portfolio consistently meets the needs of patients and practitioners, setting the company apart as a leader in this field.
Article content
Today, Galderma is well positioned to be the leader in all aspects of Injectable Aesthetics, having the in-house capabilities to discover, research, develop, manufacture, and market best-in-class products.
Article content
More details on Galderma’s scientific presentations at TOXINS 2026 can be found here.
Article content
About Relfydess (RelabotulinumtoxinA)
Article content
Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator designed with PEARL Technology that is designed to preserve molecule integrity.
Article content
1
Article content
PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.
Article content
1,7,8
Article content
Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.
Article content
9,10
Article content
It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally.
Article content
About Galderma
Article content
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:
English (US)